Moolec Science SA (MLEC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2025, filed Apr 16, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MLEC SEC filings page.
Moolec Science SA (MLEC) reported $5.6M in revenue for fiscal year 2024, up 521.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but working capital and operating losses still consume cash faster than the business converts sales.
In FY2024, operating cash flow of-$9.3M nearly matched free cash flow of-$9.5M despite capital expenditures of only$158K ; the cash drain is primarily operational rather than a heavy reinvestment program.
Revenue expanded 6.2x from FY2023 to FY2024, yet net margin deteriorated from
Inventory rose from
Financial Health Signals
Moolec Science SA does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Moolec Science SA passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Moolec Science SA reported a net loss of $7.3M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Moolec Science SA generated $2.6M in revenue in Q2 2025. This represents an increase of 948.3% from the same quarter a year earlier.
Moolec Science SA reported -$2.4M in net income in Q2 2025. This represents a decrease of 36.1% from the same quarter a year earlier.
Not reported for Q2 2025.
Not reported for Q2 2025.
Cash & Balance Sheet
Moolec Science SA held $1.9M in cash against $166K in long-term debt as of Q2 2025, with $6.5M of liabilities due within a year.
Not reported for Q2 2025.
Not reported for Q2 2025.
Margins & Returns
Moolec Science SA's net profit margin was -91.8% in Q2 2025, showing the share of revenue converted to profit. No change is given against Q2 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Moolec Science SA's ROE was -86.8% in Q2 2025, measuring profit generated per dollar of shareholder equity. This is down 60.1 percentage points from the same quarter a year earlier.
Not reported for Q2 2025.
Not reported for Q2 2025.
Capital Allocation
None of these metrics is reported for Q2 2025.
MLEC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M+948.3% | N/A | $252K | $1.7M | N/A | N/A | N/A | N/A |
| Interest Expense | $655K+611.4% | N/A | $92K | $93K+3099.6% | N/A | $86K+113.3% | N/A | -$3K |
| Income Tax | $281K+219.0% | N/A | -$236K | -$215K | N/A | N/A | N/A | N/A |
| Net Income | -$2.4M-36.1% | N/A | -$1.8M | -$1.6M-120.5% | N/A | N/A | N/A | -$721K |
| Diluted Shares (Avg) | 39M+3.1% | N/A | 38M | 38M+22.0% | N/A | 38M+21.2% | N/A | 31M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).
MLEC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.4M | $34.8M+44.6% | N/A | $22.5M | $24.1M+322.6% | $20.0M | $23.2M | N/A |
| Current Assets | $9.5M | $13.7M+157.9% | N/A | $3.2M | $5.3M+391.9% | $7.2M | $10.4M | N/A |
| Cash & Equivalents | $1.9M | $5.4M+113.2% | N/A | $854K | $2.5M+133.7% | $6.2M+421.9% | $10.4M | N/A |
| Inventory | $4.8M+865.9% | $6.3M+1248.3% | $502K | $390K | $466K | N/A | N/A | N/A |
| Accounts Receivable | $809K | $1.0M-24.0% | N/A | N/A | $1.3M | N/A | N/A | N/A |
| Goodwill | $281K | $263K+4.4% | N/A | $248K | $251K-94.5% | $4.7M | N/A | N/A |
| Total Liabilities | $28.6M | $28.0M+100.6% | N/A | $13.6M | $13.9M+241.2% | $8.4M | $11.3M | N/A |
| Current Liabilities | $6.5M | $8.2M-35.3% | N/A | $12.5M | $12.6M+208.2% | $8.4M | $11.3M | N/A |
| Non-Current Liabilities | $22.1M | $19.8M+1372.4% | N/A | $1.1M | $1.3M | $0 | $0 | N/A |
| Long-Term Debt | $166K | $249K | N/A | $244K | N/A | $2K | $1K | N/A |
| Total Equity | $2.8M-58.2% | $6.8M-32.6% | $6.7M-43.8% | $8.9M+907.1% | $10.1M+529.9% | $11.6M+278.9% | $11.9M | $883K |
| Retained Earnings | -$70.3M | -$65.9M-12.5% | N/A | -$60.2M | -$58.6M-757.8% | -$55.9M | -$55.5M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
MLEC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$3.9M-558.8% | -$1.7M-18171.8% | -$2.7M-337.6% | -$4.3M-870.6% | -$593K | $10K |
| Depreciation & Amortization | N/A | N/A | N/A | $181K+42399.5% | $121K+28311.3% | $4250.0% | $424 | $425 |
| Capital Expenditures | N/A | N/A | -$8K | $104K | $12K | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$3.9M | -$1.8M | -$2.7M | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$2.2M | -$82K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $4.8M | -$127K | $1.3M+156.3% | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.
MLEC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q4'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Net Margin | -91.8% | N/A | -707.4% | -91.4% | N/A | N/A | N/A | N/A |
| Return on Equity | -86.8%-60.1pp | N/A | -26.7% | -17.9%+63.8pp | N/A | N/A | N/A | -81.7% |
| Return on Assets | -7.7% | N/A | N/A | -7.1% | N/A | N/A | N/A | N/A |
| Current Ratio | 1.48 | 1.69+1.3x | N/A | 0.26 | 0.42+0.2x | 0.85 | 0.93 | N/A |
| Debt-to-Equity | 0.06 | 0.04-1.3x | N/A | 0.03 | 1.38+1.4x | 0.00 | 0.00 | N/A |
| Asset Turnover | 0.08 | N/A | N/A | 0.08 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | -1551.6% | -106.2% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Moolec Science SA MLEC | FY2024 | $5.6M | -$7.3M | N/A | $5.1M | — |
| Portage Biotech Inc. PRTG | FY2018 | N/A | $123.7M | N/A | $15.5M | — |
| CARISMA THERAPEUTICS INC CARM | FY2024 | $19.6M | -$60.5M | N/A | $6.4M | — |
| Minerva Neurosciences, Inc NERV | FY2025 | N/A | -$293.4M | N/A | $198.2M | — |
| Cocrystal Pharma, Inc. COCP | FY2025 | N/A | -$8.8M | N/A | $23.9M | — |
| NextCure, Inc. NXTC | FY2025 | N/A | -$55.8M | N/A | $32.0M | — |
Where Moolec Science SA Ranks
Frequently Asked Questions
What is Moolec Science SA's annual revenue?
Moolec Science SA (MLEC) reported $5.6M in total revenue for fiscal year 2024. This represents a 521.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Moolec Science SA's revenue growing?
Moolec Science SA (MLEC) revenue grew by 521.5% year-over-year, from $905K to $5.6M in fiscal year 2024.
Is Moolec Science SA profitable?
No, Moolec Science SA (MLEC) reported a net income of -$7.3M in fiscal year 2024.
How much debt does Moolec Science SA have?
As of fiscal year 2024, Moolec Science SA (MLEC) had $5.4M in cash and equivalents against $249K in long-term debt.
What is Moolec Science SA's return on equity (ROE)?
Moolec Science SA (MLEC) has a return on equity of -107.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Moolec Science SA's free cash flow?
Moolec Science SA (MLEC) recorded an outflow of $9.5M in free cash flow during fiscal year 2024. This represents a -26.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Moolec Science SA's operating cash flow?
Moolec Science SA (MLEC) recorded an outflow of $9.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Moolec Science SA's total assets?
Moolec Science SA (MLEC) had $34.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Moolec Science SA's capital expenditures?
Moolec Science SA (MLEC) invested $158K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Moolec Science SA's current ratio?
Moolec Science SA (MLEC) had a current ratio of 1.69 as of fiscal year 2024, which is generally considered healthy.
What is Moolec Science SA's debt-to-equity ratio?
Moolec Science SA (MLEC) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Moolec Science SA's return on assets (ROA)?
Moolec Science SA (MLEC) had a return on assets of -21.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Moolec Science SA's P/E ratio?
Moolec Science SA (MLEC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $5.1M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Moolec Science SA's price-to-sales ratio?
Moolec Science SA (MLEC) trades at 0.9x sales, its market capitalization divided by revenue of $5.6M revenue, FY2024. The market capitalization is $5.1M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Moolec Science SA's Piotroski F-Score?
Moolec Science SA (MLEC) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Moolec Science SA's earnings high quality?
Moolec Science SA (MLEC) reported a net loss of $7.3M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.